KALA BIO
KALA
40 hedge funds and large institutions have $30.9M invested in KALA BIO in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 15 closing their positions.
7.74% less ownership
Funds ownership: 46.74% → 39% (-7.7%)
13% less funds holding
Funds holding: 46 → 40 (-6)
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
53% less call options, than puts
Call options by funds: $69K | Put options by funds: $146K
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
70% less capital inflows, than outflows
Capital inflows: $5.43M | Capital outflows: $18.2M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$835K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$835K |
| 3 |
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$557K |
| 4 |
Virtu Financial
New York
|
+$278K |
| 5 |
Barclays
London,
United Kingdom
|
+$139K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$9.01M |
| 2 |
Caxton Corporation
Princeton,
New Jersey
|
-$3.2M |
| 3 |
BlackRock
New York
|
-$974K |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
-$527K |
| 5 |
ACT Capital Management
Wayne,
Pennsylvania
|
-$498K |
KALA Hedge Fund Activity: Q4 2021 in Review
40 of the 6,524 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q4 2021, worth a combined $30.9M — down 61% from $79.7M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of KALA and 9 opened new positions — a net loss of 6 holders — while 9 trimmed existing stakes and 3 added.
The largest buyer was Bank of America, adding an estimated $835K. The largest seller was OrbiMed, exiting entirely with an estimated $9.01M sold.
- 40 institutional investors held KALA BIO (KALA) as of Q4 2021, down from 46 in Q3 2021.
- Funds reported $30.9M of KALA BIO stock for Q4 2021, down 61% quarter-over-quarter.
- 9 funds opened new KALA BIO positions in Q4 2021 and 15 closed out, a net change of -6 holders.
- The largest KALA BIO buyer in Q4 2021 was Bank of America, an estimated $835K added.
- The largest KALA BIO seller in Q4 2021 was OrbiMed, an estimated $9.01M sold.
Based on aggregated 13F filings for Q4 2021.